Yujia Wen

940 total citations
28 papers, 623 citations indexed

About

Yujia Wen is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, Yujia Wen has authored 28 papers receiving a total of 623 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 13 papers in Cancer Research and 11 papers in Oncology. Recurrent topics in Yujia Wen's work include Renal cell carcinoma treatment (7 papers), Cancer Genomics and Diagnostics (6 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Yujia Wen is often cited by papers focused on Renal cell carcinoma treatment (7 papers), Cancer Genomics and Diagnostics (6 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Yujia Wen collaborates with scholars based in United States, Canada and China. Yujia Wen's co-authors include M. Eileen Dolan, R. Stephanie Huang, Dana Ziliak, Eric R. Gamazon, Hae Kyung Im, Claudia Wing, Nancy J. Cox, Shiwei Duan, Wasim K. Bleibel and Wei Zhang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Scientific Reports.

In The Last Decade

Yujia Wen

27 papers receiving 617 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yujia Wen United States	10	359	307	228	86	58	28	623
Lyn M. Huff United States	15	305 0.8×	106 0.3×	366 1.6×	78 0.9×	90 1.6×	18	570
Kimie Kondo United States	15	484 1.3×	127 0.4×	259 1.1×	65 0.8×	61 1.1×	22	793
Rie Shibuya Japan	12	305 0.8×	267 0.9×	220 1.0×	56 0.7×	20 0.3×	27	642
James Sherwood United Kingdom	9	181 0.5×	269 0.9×	183 0.8×	208 2.4×	27 0.5×	15	524
Vanessa S. Silveira Brazil	16	430 1.2×	102 0.3×	117 0.5×	32 0.4×	85 1.5×	32	648
Viktor Hlaváč Czechia	13	280 0.8×	168 0.5×	260 1.1×	57 0.7×	20 0.3×	35	475
Sarah Troutman United States	8	173 0.5×	70 0.2×	169 0.7×	91 1.1×	30 0.5×	13	362
CA Eekman Netherlands	8	384 1.1×	96 0.3×	465 2.0×	64 0.7×	91 1.6×	8	725
Kasper Langebjerg Andersen Denmark	10	418 1.2×	295 1.0×	283 1.2×	73 0.8×	16 0.3×	17	938
Natsuko Inoue Japan	12	233 0.6×	88 0.3×	232 1.0×	26 0.3×	74 1.3×	16	450

Countries citing papers authored by Yujia Wen

Since Specialization

Citations

This map shows the geographic impact of Yujia Wen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yujia Wen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yujia Wen more than expected).

Fields of papers citing papers by Yujia Wen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yujia Wen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yujia Wen. The network helps show where Yujia Wen may publish in the future.

Co-authorship network of co-authors of Yujia Wen

This figure shows the co-authorship network connecting the top 25 collaborators of Yujia Wen. A scholar is included among the top collaborators of Yujia Wen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yujia Wen. Yujia Wen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dercle, Laurent, Susan M. Geyer, Andrew B. Nixon, et al.. (2025). Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance). ESMO Open. 10(12). 105848–105848.

Stover, Daniel G., Roberto Salgado, Karla V. Ballman, et al.. (2024). Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502. npj Breast Cancer. 10(1). 75–75. 4 indexed citations

Gupta, Shilpa, Karla V. Ballman, Andrea B. Apolo, et al.. (2024). MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab (Av) vs Av after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).. Journal of Clinical Oncology. 42(4_suppl). TPS714–TPS714. 2 indexed citations

Gupta, Shilpa, Karla V. Ballman, Matt D. Galsky, et al.. (2023). MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).. Journal of Clinical Oncology. 41(16_suppl). TPS4609–TPS4609. 1 indexed citations

Stover, Daniel G., Roberto Salgado, Oleksandr Savenkov, et al.. (2023). Association of tumor infiltrating lymphocyte quantity with survival in patients (pts) with metastatic breast cancer (MBC) receiving microtubule-targeting agents: Post hoc analysis CALGB 40502 (Alliance).. Journal of Clinical Oncology. 41(16_suppl). 1010–1010. 2 indexed citations

Symmans, W. Fraser, Yujia Wen, Charles M. Perou, et al.. (2022). Challenges and Gaps in Clinical Trial Genomic Data Management. JCO Clinical Cancer Informatics. 6(6). e2100193–e2100193. 2 indexed citations

Gupta, Shilpa, Karla V. Ballman, Matt D. Galsky, et al.. (2022). MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001).. Journal of Clinical Oncology. 40(16_suppl). TPS4607–TPS4607. 9 indexed citations

McConkey, David J., Woonyoung Choi, Susan Halabi, et al.. (2022). Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) phase 3 clinical trial of gemcitabine and cisplatin (GC) plus bevacizumab (B) or placebo (P).. Journal of Clinical Oncology. 40(16_suppl). 4562–4562. 1 indexed citations

Holleran, Julianne L., Robert A. Parise, Michelle A. Rudek, et al.. (2021). Quantitation of Cabozantinib in Human Plasma by LC–MS/MS. Journal of Chromatographic Science. 60(3). 274–279. 2 indexed citations

10.

Zhang, Tian, Karla V. Ballman, Atish D. Choudhury, et al.. (2021). PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).. Journal of Clinical Oncology. 39(6_suppl). TPS366–TPS366. 15 indexed citations

11.

Kozono, David, Elad Sharon, Jennifer Le‐Rademacher, et al.. (2020). Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events.. Journal of Clinical Oncology. 38(15_suppl). TPS3154–TPS3154. 4 indexed citations

12.

Gamazon, Eric R., Matthew R. Trendowski, Yujia Wen, et al.. (2018). Gene and MicroRNA Perturbations of Cellular Response to Pemetrexed Implicate Biological Networks and Enable Imputation of Response in Lung Adenocarcinoma. Scientific Reports. 8(1). 733–733. 12 indexed citations

13.

Wen, Yujia, Theodore Karrison, George L. Bakris, et al.. (2014). Sorafenib Dose Escalation Is Not Uniformly Associated With Blood Pressure Elevations in Normotensive Patients With Advanced Malignancies. Clinical Pharmacology & Therapeutics. 96(1). 27–35. 11 indexed citations

14.

Bockhorn, Jessica, Rachel Dalton, Chika Nwachukwu, et al.. (2013). MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nature Communications. 4(1). 1393–1393. 203 indexed citations

15.

Giacomini, Kathleen M., Praveen Balimane, Michael T. Eadon, et al.. (2013). International Transporter Consortium Commentary on Clinically Important Transporter Polymorphisms. Clinical Pharmacology & Therapeutics. 94(1). 23–26. 120 indexed citations

16.

Ziliak, Dana, Eric R. Gamazon, Bonnie LaCroix, et al.. (2012). Genetic Variation That Predicts Platinum Sensitivity Reveals the Role of miR-193b* in Chemotherapeutic Susceptibility. Molecular Cancer Therapeutics. 11(9). 2054–2061. 30 indexed citations

17.

Huang, R. Stephanie, Eric R. Gamazon, Dana Ziliak, et al.. (2011). Population differences in microRNA expression and biological implications. RNA Biology. 8(4). 692–701. 127 indexed citations

18.

Wen, Yujia, et al.. (2011). Chemotherapeutic-induced apoptosis. Pharmacogenetics and Genomics. 21(8). 476–488. 17 indexed citations

19.

Wen, Yujia, Eric R. Gamazon, Wasim K. Bleibel, et al.. (2011). An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers. Human Molecular Genetics. 21(7). 1470–1480. 14 indexed citations

20.

Liu, Mingqiu, et al.. (2002). Sequence analysis and characterization of plasmid pSFD10 from Salmonella choleraesuis. Plasmid. 48(1). 59–63. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact